WallStreetZenWallStreetZen

NASDAQ: ALKS
Alkermes PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ALKS

Based on 11 analysts offering 12 month price targets for Alkermes PLC

Min Forecast
$35.00+18.52%
Avg Forecast
$44.00+49%
Max Forecast
$55.00+86.25%

Should I buy or sell ALKS stock?

Based on 11 analysts offering ratings for Alkermes PLC.

Strong Buy
Strong Buy
6 analysts 54.55%
Buy
3 analysts 27.27%
Hold
2 analysts 18.18%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Buy" agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their ALKS stock forecasts and price targets.

ALKS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-17Find Out Why
lockedlocked$00.00+00.00%2025-11-13
lockedlocked$00.00+00.00%2025-11-13
lockedlocked$00.00+00.00%2025-10-29
lockedlocked$00.00+00.00%2025-10-27
Piper Sandler
Top 5%
96
Strong BuyReiterates$45.00+52.39%2025-10-23
RBC Capital
Top 5%
96
BuyMaintains$47.00+59.16%2025-10-23
JP Morgan
Top 3%
98
HoldMaintains$35.00+18.52%2025-09-09
HC Wainwright & Co.
Top 3%
98
HoldReiterates$46.00+55.77%2025-09-09
Goldman Sachs
Top 41%
60
Strong BuyInitiates Coverage On$43.00+45.61%2025-07-15

1 of 2

Forecast return on equity

Is ALKS forecast to generate an efficient return?

Company
20.21%
Industry
285.76%
Market
229.18%
ALKS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ALKS forecast to generate an efficient return on assets?

Company
15.04%
Industry
157.24%
ALKS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ALKS earnings per share forecast

What is ALKS's earnings per share in the next 3 years based on estimates from 18 analysts?

Avg 1 year Forecast
$1.51-27.2%
Avg 2 year Forecast
$1.52-26.44%
Avg 3 year Forecast
$1.53-26.09%
ALKS's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

ALKS revenue forecast

What is ALKS's revenue in the next 3 years based on estimates from 18 analysts?

Avg 1 year Forecast
$1.5B-1.47%
Avg 2 year Forecast
$1.9B+22.39%
Avg 3 year Forecast
$1.9B+23.18%
ALKS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ALKS earnings growth forecast

How is ALKS forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
-9.55%
Industry
364.93%
Market
42.83%
ALKS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
ALKS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
ALKS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

ALKS revenue growth forecast

How is ALKS forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
8.55%
Industry
132.47%
Market
25.64%
ALKS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ALKS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ALKS vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
ALKS$29.53$44.00+49.00%Strong Buy
INDV$34.02$32.50-4.47%Strong Buy
LNTH$59.77$74.17+24.09%Buy
AMRX$12.18$13.50+10.84%Strong Buy
RGC$13.01N/AN/A
View Top Pharmaceutical Stocks

Alkermes Stock Forecast FAQ

Is Alkermes Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 11 Wall Street analysts covering (NASDAQ: ALKS) stock is to Strong Buy ALKS stock.

Out of 11 analysts, 6 (54.55%) are recommending ALKS as a Strong Buy, 3 (27.27%) are recommending ALKS as a Buy, 2 (18.18%) are recommending ALKS as a Hold, 0 (0%) are recommending ALKS as a Sell, and 0 (0%) are recommending ALKS as a Strong Sell.

If you're new to stock investing, here's how to buy Alkermes stock.

What is ALKS's earnings growth forecast for 2025-2027?

(NASDAQ: ALKS) Alkermes's forecast annual earnings growth rate of -9.55% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 364.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.83%.

Alkermes's earnings in 2025 is $338,826,000.On average, 18 Wall Street analysts forecast ALKS's earnings for 2025 to be $248,815,574, with the lowest ALKS earnings forecast at $226,541,222, and the highest ALKS earnings forecast at $279,131,149. On average, 18 Wall Street analysts forecast ALKS's earnings for 2026 to be $251,424,431, with the lowest ALKS earnings forecast at $181,232,978, and the highest ALKS earnings forecast at $402,226,252.

In 2027, ALKS is forecast to generate $252,629,789 in earnings, with the lowest earnings forecast at $21,035,971 and the highest earnings forecast at $563,463,499.

What is ALKS's revenue growth forecast for 2025-2027?

(NASDAQ: ALKS) Alkermes's forecast annual revenue growth rate of 8.55% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.47%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.64%.

Alkermes's revenue in 2025 is $1,521,338,000.On average, 18 Wall Street analysts forecast ALKS's revenue for 2025 to be $247,511,145,991, with the lowest ALKS revenue forecast at $234,301,745,271, and the highest ALKS revenue forecast at $258,739,136,603. On average, 18 Wall Street analysts forecast ALKS's revenue for 2026 to be $307,448,801,758, with the lowest ALKS revenue forecast at $284,662,585,516, and the highest ALKS revenue forecast at $331,555,958,072.

In 2027, ALKS is forecast to generate $309,430,211,866 in revenue, with the lowest revenue forecast at $227,201,692,384 and the highest revenue forecast at $367,716,692,543.

What is ALKS's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ALKS) forecast ROA is 15.04%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 157.24%.

What is ALKS's Price Target?

According to 11 Wall Street analysts that have issued a 1 year ALKS price target, the average ALKS price target is $44.00, with the highest ALKS stock price forecast at $55.00 and the lowest ALKS stock price forecast at $35.00.

On average, Wall Street analysts predict that Alkermes's share price could reach $44.00 by Nov 17, 2026. The average Alkermes stock price prediction forecasts a potential upside of 49% from the current ALKS share price of $29.53.

What is ALKS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ALKS) Alkermes's current Earnings Per Share (EPS) is $2.07. On average, analysts forecast that ALKS's EPS will be $1.51 for 2025, with the lowest EPS forecast at $1.37, and the highest EPS forecast at $1.69. On average, analysts forecast that ALKS's EPS will be $1.52 for 2026, with the lowest EPS forecast at $1.10, and the highest EPS forecast at $2.44. In 2027, ALKS's EPS is forecast to hit $1.53 (min: $0.13, max: $3.41).

What is ALKS's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ALKS) forecast ROE is 20.21%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.